Participants with unexplained anemia, and/or thrombocytopenia
Known coagulopathy, platelet disorder or history of non-drug-induced thrombocytopenia
History of thrombocytopenia with complications
Known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.
Have a history of thrombocytopenia with complications
DONOR: Thrombocytopenia < 150,000 cells /mm^3 at baseline evaluation
Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
Thrombocytopenia <100 x 103/ml, not resulting from therapy
Patients with documented contraindication to anticoagulation therapy such as heparin induced thrombocytopenia or a documented coagulopathy or hematologic disorder that would contraindicated undergoing treatment and use of the associated anticoagulant agents required during treatment
Patients with a history of hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.
Thrombocytopenia (< 125,000 platelets/mm^3)
Platelets ? 75,000/mcL OR ? 50.000 if thrombocytopenia due to iBCL
Secondary immune thrombocytopenia from any cause including lymphoma, chronic lymphocytic leukemia, and drug-induced thrombocytopenia
hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x10^9/L or history of heparin induced thrombocytopenia;
History of coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia
Subjects with coagulopathies, including thrombocytopenia
Platelets < 30,000/ mm3 for any reason, PT prolongation or thrombocytopenia that is not due to sepsis.
History of adverse reaction to heparin such as heparin-induced thrombocytopenia
Patients with known heparin induced thrombocytopenia
Known other causes of thrombocytopenia
Participants with known coagulopathy, platelet disorder or history of non-drug-induced thrombocytopenia
A history of heparin-induced thrombocytopenia or hypersensitivity to heparin, enoxaparin, or pork products
Secondary immune thrombocytopenia
Drug induced thrombocytopenia
Thrombocytopenia (<30,000/uL)
Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/?L).
History of heparin-induced thrombocytopenia.
Active autoimmune thrombocytopenia.
Known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia
Platelets < 150 mg/dL or history of thrombocytopenia
Thrombocytopenia
History of heparin induced thrombocytopenia
Known allergy to heparin or aspirin or a history of heparin induced thrombocytopenia
Grade >= 3 thrombocytopenia (platelets < 50 x 10^9/L) after the first 3 months of therapy with the TKI for patients with CML and platelets < 100 x 10^9/L for patients with MF after the first 3 months of therapy; thrombocytopenia must be either recurrent (i.e., second or greater episode of thrombocytopenia) or having required dose reductions of the TKI
Thrombocytopenia that is considered to be unrelated to treatment with TKI or accelerated phase as defined above
History of heparin induced thrombocytopenia
Thrombocytopenia (platelet count < 50,000)
Thrombocytopenia < 150 x 10(9)/L (< 150,000/ÂµL) at baseline evaluation.
Thrombocytopenia (platelets < 100,000 cells/uL)
